ERBB2 and cancer: To improve peptide stability, D-amino acids were introduced into the peptide, which resulted in an IC50 value in the nanomolar range in HER2-overexpressing cancer cell lines, as well as an increase in stability both in vitro and in vivo to 48 and 12 h, respectively [181].